<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02809534</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-08-II</org_study_id>
    <nct_id>NCT02809534</nct_id>
  </id_info>
  <brief_title>A Study of Anlotinib in Patients With Hepatocellular Carcinoma</brief_title>
  <acronym>ALTER0802</acronym>
  <official_title>A Single Group, Open Label, Single-center Clinical Trial to Assess the Efficacy and Safety of Anlotinib in Patients With Hepatocellular Carcinoma (ALTER0802)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the primary effects and safety of Anlotinib with placebo in patients with
      Hepatocellular Carcinoma(HCC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-week Progression-free survival rate(PFR 12w)</measure>
    <time_frame>From randomization，each 42 days up to PD or death(up to 24 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression(TTP)</measure>
    <time_frame>From randomization，each 42 days up to PD or death(up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-week Progression-free survival rate(PFR 24w)</measure>
    <time_frame>From randomization，each 42 days up to PD or death(up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Alpha-Fetoprotein level (AFP)</measure>
    <time_frame>From randomization up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomization until death (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Anlotinib p.o. qd</description>
    <arm_group_label>Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Conform to the clinical diagnosis standard strictly or histological or cytological
             confirmation of hepatocellular carcinoma who cannot benefit from treatments of
             ablative therapy

          -  Liver function status Child-Pugh Class A or B (score≤8)

          -  Enroll 2 group patients：Group A：No history of systematic chemotherapy/target
             therapy.Group B:Failed with Sorafenib(Last Sorafenib Therapy≥4 weeks )

          -  Last Therapy≥4 weeks (such as surgery, PCI,ablation, radiotherapy)，and the wound
             healing.Patients with adjuvant chemotherapy, last chemotherapy ≥6m

          -  At least one measurable lesion (by RECIST1.1)

          -  18-75 years,ECOG PS:0-1,Life expectancy of more than 3 months

          -  Main organs function is normal

          -  Women of childbearing potential should agree to use and utilize an adequate method of
             contraception (such as intrauterine device，contraceptive and condom) throughout
             treatment and for at least 6 months after study is stopped；the result of serum or
             urine pregnancy test should be negative within 7 days prior to study enrollment，and
             the patients required to be non-lactating；Man participants should agree to use and
             utilize an adequate method of contraception throughout treatment and for at least 6
             months after study is stopped

          -  Patients should participate in the study voluntarily and sign informed consent

        Exclusion Criteria:

          -  Diagnosed with cholangiocellular carcinoma, mixed cell carcinoma and fibrolamellar
             hepatocellular carcinoma

          -  History of other malignancy (except for non-melanoma skin cancer, cervix in situ
             carcinoma)

          -  Liver function status Child-Pugh Class C (score&gt;9),with malignant ascites

          -  HBV-DNA&gt;2000IU/mL

          -  History of liver transplantation or prepare for it

          -  Patients with any severe and/or unable to control diseases，including：

               1. Blood pressure unable to be controlled ideally(systolic pressure≥150
                  mmHg，diastolic pressure≥100 mmHg);

               2. Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or
                  malignant arrhythmias(including QT≥480ms) and patients with Grade 1 or higher
                  congestive heart failure (NYHA Classification);

               3. Patients with active or unable to control serious infections;

               4. Patients with poorly controlled diabetes (fasting blood glucose(FBG)＞10mmol/L)

               5. Urine protein ≥ ++，and 24-hour urinary protein excretion＞1.0 g confirmed

          -  Patients with arterial or venous thromboembolic events occurred within 6 months, such
             as cerebrovascular accident (including transient ischemic attack), deep vein
             thrombosis and pulmonary embolism

          -  Patients with drug abuse history and unable to get rid of or Patients with mental
             disorders

          -  Imaging showed tumors have involved important blood vessels or by investigators
             determine likely during the follow-up study and cause fatal hemorrhage

          -  Patients participated in other anticancer drug clinical trials within 4 weeks

          -  History of immunodeficiency

          -  Patients with concomitant diseases which could seriously endanger their own safety or
             could affect completion of the study according to investigators' judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aiping Zhou, doctor</last_name>
    <email>zhouap1825@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aiping Zhou, doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <last_update_submitted>September 4, 2016</last_update_submitted>
  <last_update_submitted_qc>September 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anlotinib</keyword>
  <keyword>AL3818</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

